Syneos Health
↗Morrisville, North Carolina, USA
Syneos Health is a global Contract Research Organization (CRO) and Contract Commercial Organization (CCO) formed from the 2018 merger of INC Research (founded 1998) and InVentiv Health. The company provides integrated biopharmaceutical solutions spanning the entire clinical-to-commercial spectrum, including clinical development services, regulatory support, and commercial/medical affairs capabilities. Syneos Health has helped develop or commercialize 96% of novel oncology drugs approved by the FDA and 93% of oncology products granted marketing authorization by the EMA in recent five-year periods. The company operates through AI- and tech-enabled platforms designed to improve performance, reduce risk, and accelerate the delivery of therapies to patients worldwide. As of September 2023, the company was taken private by a consortium of Elliott Investment Management, Patient Square Capital, and Veritas Capital.
CLASSIFICATION
Company Type:CRO
Therapeutic Areas:
Industry:Contract Research Organization (CRO) / Biopharmaceutical Services
Sub-Industry:Clinical Development Services, Commercial Services, Medical Affairs
SIZE & FINANCIALS
Employees:10000+
Revenue:$5.2B-$5.4B (2022 was $5.39B; 2023 projected $4.9B-$5.1B)
Founded:2018
Ownership:private
Status:acquired
FUNDING
Stage:Post-IPO private acquisition
Investors:Elliott Investment Management, Patient Square Capital, Veritas Capital
STOCK
Exchange:formerly NASDAQ (delisted)
Ticker:SYNH (formerly, delisted 2023-09-28)
PIPELINE
Stage:Not applicable - Syneos Health supports client pipelines across all stages (Discovery to Commercial)
Lead Drug Stage:Not applicable
Modalities:Not applicable - CRO/service provider, not drug developer
CORPORATE STRUCTURE
Parent Company:Consortium (Elliott Investment Management, Patient Square Capital, Veritas Capital)
Acquired By:Consortium of Elliott Investment Management, Patient Square Capital, and Veritas Capital (2023-09-28)
Subsidiaries:RxDataScience, StudyKIK
Key Partnerships:Crossject (U.S. commercial launch support for Zepizure), CytoDyn (Phase II oncology trial CRO services, 2024), ACTIVATO (clinical trials support in Japan, 2025), Pacific Clinical Research Network (clinical trials support in New Zealand, 2024)
COMPETITION
Position:Leader
Competitors:IQVIA, Parexel, Covance (LabCorp subsidiary), ICON plc, PPD, Medidata, PRA Health Sciences
LEADERSHIP
Key Executives:
Costa Panagos - Chief Executive Officer
Colin Shannon - Executive Chairman
Michael Bonello - Chief Financial Officer
Michael Brooks - Chief Operating Officer
Christian Tucat - Chief Business Officer
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Syneos Health. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.